Douglas Hanahan


Douglas Hanahan is an American biologist, professor, and Director Emeritus of the Swiss Institute for Experimental Cancer Research at EPFL in Lausanne, Switzerland. He is a Distinguished Scholar at the Lausanne branch of the Ludwig Institute for Cancer Research.

Education and early career

Hanahan received a bachelor's degree in physics from the Massachusetts Institute of Technology in 1976 and earned his Ph.D. in biophysics from Harvard University in 1983 as a Harvard Society of Fellows member.
He conducted research at Cold Spring Harbor Laboratory, first as a graduate student and later as a faculty member. During his tenure, he developed methodologies to facilitate the molecular cloning of genes in E. coli, a foundational tool in life sciences.

Research

Hanahan pioneered the genetic engineering of transgenic mouse models to study human cancer. In collaboration with Judah Folkman, he discovered the “angiogenic switch,” a process that enables new blood vessel formation and facilitates tumor progression towards malignancy.
Dr. Hanahan spent twenty-one years at the University of California San Francisco, in the UCSF Diabetes Center prior to EPFL in 2009. During that time, Hanahan co-authored a seminal paper with Robert Weinberg entitled The Hallmarks of Cancer, which proposed a conceptual framework for understanding the complexity of cancer development. This was followed by updated reviews in 2011 and 2022.
He was instrumental in founding the Swiss Cancer Center Leman, the first comprehensive cancer center in Switzerland. Hanahan also played a key role in developing the Agora Translational Cancer Research Center, a collaborative facility designed to advance cancer research and therapy.

Awards and honors